TWD
CRBP icon

True Wealth Design’s Corbus Pharmaceuticals CRBP Stock Holding History

True Wealth Design’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-63
Closed -$1.3K – 1397
2024
Q3 		$1.3K Buy
+63
New +$3.22K ﹤0.01% 905

Other funds holding CRBP

CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
Altium Capital Management New York $42M AUM
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

True Wealth Design's CRBP Position: Q4 2024 in Review

True Wealth Design sold out of Corbus Pharmaceuticals (CRBP) in Q4 2024, closing a stake of 63 shares — an estimated $1.3K sold.

True Wealth Design first reported a position in CRBP in Q3 2024 and held it in 1 quarter. The position peaked at $1.3K in Q3 2024. 99 funds tracked by Wall St. Rank hold CRBP as of Q4 2024.

  • True Wealth Design reported no remaining Corbus Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • True Wealth Design sold 63 Corbus Pharmaceuticals shares in Q4 2024, an estimated $1.3K.
  • True Wealth Design first reported a position in Corbus Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • True Wealth Design's Corbus Pharmaceuticals position peaked at $1.3K in Q3 2024.
  • 99 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q4 2024.

Based on True Wealth Design's 13F filing for Q4 2024, filed 14 Feb 2025.